Zivo Bioscience, Inc. (ZIVO): Nasdaq/NYSE listing notice — Zivo Bioscience receives Nasdaq delisting notice for $2.5M equity non-compliance

Zivo Bioscience, Inc.

Nasdaq notified Zivo on May 23, 2023 that it fails to meet $2.5M stockholders' equity requirement (Listing Rule 5550(b)).
Company plans to request a hearing before Nasdaq Hearings Panel to stay delisting pending compliance plan.
Previously granted extension to evidence compliance expired May 22, 2023; company was unable to cure.
No assurance that Panel will grant continued listing or that company can regain compliance within any extension.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Zivo Bioscience, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)

Exact text from the filing

May 23, 2023, Zivo Biosciences, Inc. (the “Company”) was notified by the Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b) (the “Rule”), as of May 22, 2023, the Company’s common stock was subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing bef

View on SEC.gov

Browse all listing & compliance notices →

Zivo Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-007294

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.